Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used. This brief explores variation in use of the first two monoclonal antibodies from November 2020 through March 2021, and identifies potential disparities in uptake by social vulnerability and urbanicity.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Allison Kolbe, (202) 839-1508, Allison.Kolbe@hhs.gov. Content will be updated pending the outcome of the Section 508 review.
- Unvaccinated for COVID-19 but Willing: Demographic Factors, Geographic Patterns, and Changes Over Time
- Vaccine Hesitancy for COVID-19: State, County, and Local Estimates
- Health Disparities by Race and Ethnicity During the COVID-19 Pandemic: Current Evidence and Policy Approaches
- Disparities in COVID-19 Vaccination Rates Across Racial and Ethnic Minority Groups in the United States